115 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
61 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Recombinant Interferon Alfa-2b
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 88
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01708941
62 Not yet recruiting Internet-Based Weight-Loss Program for Colorectal Cancer Survivors
Conditions: Cancer Survivor;   Colorectal Cancer;   Weight Changes
Intervention: Behavioral: Internet weight loss intervention
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Health Services Research;   Masking: Open Label
Number Enrolled: 60
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01032590
63 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Adult Solid Neoplasm;   Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Riluzole;   Drug: Sorafenib Tosylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 36
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01303341
64 Not yet recruiting PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Adult Solid Neoplasm
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: PARP Inhibitor BMN-673;   Other: Pharmacological Study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 72
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02317874
65 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 600
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01808573
66 Recruiting Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Condition: Metastatic Castrate Resistant Prostate Cancer
Interventions: Biological: DCVAC;   Biological: Placebo;   Drug: Docetaxel;   Drug: Taxotere
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator)
Number Enrolled: 1170
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT02111577
67 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / Industry / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1486
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01809691
68 Recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 90
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02187783
69 Recruiting Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Conditions: Bladder Cancer;   Urothelial Carcinoma
Interventions: Drug: OGX-427;   Drug: Docetaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 200
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01780545
70 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 175
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01836029
71 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH / Other
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 54
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02015104
72 Unknown  Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Untreated Advanced Non-Small Cell Lung Cancer
Intervention: Drug: Avastin, Alimta
Study Type: Interventional
Phase: Phase 2
Funder Type: Other
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled:
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00254319
73 Recruiting The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
Condition: Breast Neoplasms
Intervention: Other: endocrine therapy alone without radiotherapy
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 200
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT02400190
74 Not yet recruiting Adjuvant Sequential Intravesical BCG and Electromotive Mitomycin-C (EMDA/MMC) After Transuretheral Resection in Patients With Primary High Risk Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder. A One-group Phase II Study.
Condition: Bladder Carcinoma
Intervention: Device: Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 50
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02202044
75 Recruiting Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Condition: Acute Myeloid Leukemia
Interventions: Drug: Phase I- Cytarabine & Eltrombopag;   Drug: Phase II- Sequence A;   Drug: Phase II- Sequence B
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator)
Number Enrolled: 90
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01656252
76 Recruiting Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Condition: Stage IV Pancreatic Cancer
Interventions: Drug: nab-paclitaxel;   Drug: Cisplatin;   Drug: gemcitabine
Study Type: Interventional
Phases: Phase 1 / Phase 2
Funder Type: Other
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 25
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01893801
77 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
Study Type: Expanded Access
Phase:
Funder Type: Industry
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01947608
78 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 460
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01757535
79 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Investigator)
Number Enrolled: 165
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01841736
80 Recruiting Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Nivolumab;   Other: Placebo matching Ipilimumab;   Other: Placebo matching Nivolumab
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 800
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT02388906

First Page    Show previous page of results Previous Page (41-60) Studies Shown (61-80) Next Page (81-100) Show next page of results    Last Page
Indicates status has not been verified in more than two years